4.5 Article

Development of the IBD Disk: A Visual Self-administered Tool for Assessing Disability in Inflammatory Bowel Diseases

Journal

INFLAMMATORY BOWEL DISEASES
Volume 23, Issue 3, Pages 333-340

Publisher

OXFORD UNIV PRESS INC
DOI: 10.1097/MIB.0000000000001033

Keywords

IBD disability index; disability; quality of life; patient outcome assessment; severity of illness index

Funding

  1. AbbVie
  2. Steering Committee
  3. Bristol-Myers Squibb
  4. Janssen
  5. MSD
  6. Pfizer
  7. Receptos
  8. Shire
  9. Takeda
  10. Chiesi
  11. Ferring
  12. Hospira
  13. Mitsubishi Pharma
  14. Celltrion
  15. Prometheus
  16. Biocodex
  17. Vifor Pharma
  18. Mundipharma
  19. Medtronic
  20. Boehringer-Ingelheim
  21. Falk
  22. Mitsubishi Tanabe
  23. Tillotts Pharma
  24. Zeria
  25. Fresenius Kabi
  26. Merck
  27. Genentech
  28. Mitsubishi
  29. Norgine
  30. Tillots
  31. Vifor
  32. Therakos
  33. Pharmacosmos
  34. Pilege
  35. BMS
  36. UCB-pharma
  37. Biogaran
  38. Boerhinger-Ingelheim
  39. Lilly
  40. HAC-Pharma
  41. Index Pharmaceuticals
  42. Amgen
  43. Sandoz
  44. Forward Pharma GmbH
  45. Celgene
  46. Biogen
  47. Lycera
  48. Samsung Bioepis

Ask authors/readers for more resources

Background: The Inflammatory bowel disease (IBD) Disability Index is a validated tool that evaluates functional status; however, it is used mainly in the clinical trial setting. We describe the use of an iterative Delphi consensus process to develop the IBD Disk-a shortened, self-administered adaption of the validated IBD Disability Index-to give immediate visual representation of patient-reported IBD-related disability. Methods: In the preparatory phase, the IBD CONNECT group (30 health care professionals) ranked IBD Disability Index items in the perceived order of importance. The Steering Committee then selected 10 items from the IBD Disability Index to take forward for inclusion in the IBD Disk. In the consensus phase, the items were refined and agreed by the IBD Disk Working Group (14 gastroenterologists) using an online iterative Delphi consensus process. Members could also suggest new element(s) or recommend changes to included elements. The final items for the IBD Disk were agreed in February 2016. Results: After 4 rounds of voting, the following 10 items were agreed for inclusion in the IBD Disk: abdominal pain, body image, education and work, emotions, energy, interpersonal interactions, joint pain, regulating defecation, sexual functions, and sleep. All elements, except sexual functions, were included in the validated IBD Disability Index. Conclusions: The IBD Disk has the potential to be a valuable tool for use at a clinical visit. It can facilitate assessment of inflammatory bowel disease-related disability relevant to both patients and physicians, discussion on specific disability-related issues, and tracking changes in disease burden over time.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available